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Evaluation of Calcitonin Use for Hypercalcemia at
Parkview Health

Alison Rydell, PharmD Candidate1; Jesse Christman, PharmD, BCOP2; Jamie Gaul, PharmD, BCPS2
1. Butler University College of Pharmacy, Indianapolis, Indiana
2. Parkview Regional Medical Center, Fort Wayne, Indiana

OBJECTIVE
•

Evaluate the appropriateness of calcitonin use for hypercalcemia at
Parkview Health, a not-for-profit community hospital health system

BACKGROUND
• Hypercalcemia is an oncologic emergency that occurs in up to 30% of
patients with active malignancy1 and can lead to life-threatening
consequences, like arrhythmias and comas.2
• It is also a common manifestation of hyperparathyroidism.3
• First-line treatment for hypercalcemia is rapid volume expansion with
intravenous (IV) crystalloid fluids3, followed by bisphosphonates.4
• Calcitonin is an appropriate second line option for patients with severe
and symptomatic hypercalcemia that has not been corrected by first-line
therapies.3 RANK-L inhibitors are an alternative second line option.5
• The mechanism of action of calcitonin is the inhibition of bone resorption
and increased excretion of electrolytes by decreasing calcium and
phosphorus reabsorption in the kidney.4
• Calcitonin is available as an injectable product and an intranasal product.
Only the injection is appropriate for treatment of hypercalcemia. The
recommended dosing is 4 units/kg subcutaneously every 12 hours.6

METHODS
• Retrospective analysis conducted within 8 community hospitals
• Inclusion criteria:
• Received at least one dose of nasal or injectable calcitonin from
•

•
•
•

•

January 1, 2019 to December 31, 2020 at any hospital within the
Parkview Health system
Exclusion criteria:
• Patients < 18 years of age
• Use for non-hypercalcemic indication
• Received nasal calcitonin on an outpatient basis
• Chronic hemodialysis patient
Data was extracted from the institution’s electronic medical record and
manually validated
Patients were classified based on corrected calcium value:
• Mild hypercalcemia: 10.5-11.9 mg/dL
• Moderate hypercalcemia: 12-13.9 mg/dL
• Severe hypercalcemia: > 14 mg/dL
Presence of clinical manifestations of hypercalcemia were manually
recorded via chart review (hypertension, bradycardia, excess urine
output, nephrolithiasis, vomiting, acute kidney injury (AKI), and altered
mental status)
• AKI was defined as an increase in serum creatinine by 1.5 times
baseline or increase by 0.3 mg/dL in 48 hours
• Hypertension and bradycardia were defined as at least 2 episodes of
SBP > 130 mmHg or DBP > 80 mmHg or HR < 60 bpm, respectively
Concomitant and previous utilization of IV fluids, bisphosphonate, and
RANK-L inhibitor use(s) were recorded to assess appropriate place in
therapy relative to calcitonin doses

RESULTS

RESULTS

• 118 patients screened for inclusion, 21 excluded  97 patients included in
analysis
• Most (81%) excluded patients received calcitonin for osteoporosis

DISCUSSION & CONCLUSIONS
• Fourteen (14.4%) patients were classified as having severe,
symptomatic hypercalcemia refractory to first-line therapies, thus
appropriate for calcitonin administration
• No patients in this population received a RANK-L inhibitor, which is
expected, as these agents are restricted to outpatient use per hospital
policy
• Based on this medication use evaluation, there is opportunity for
process improvement to standardize care
• Limiting calcitonin to second line use will promote guideline
management of hypercalcemia and yield significant cost savings
• Eliminating nasal calcitonin use for hypercalcemia will avoid delays in
appropriate care
• Limitations:
• Use of manual chart search to identify clinical manifestations is
limited by variable phrasing used by physicians that differs from the
predefined chart search terms
• Many patients were discharged before achieving eucalcemia,
resulting in difficulty assessing overall calcitonin efficacy
• Dosing protocols are needed to promote the appropriate use of
injectable calcitonin for hypercalcemia
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